Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | GOYAL PHARMACEUTICALSLikely | 5 | ₹33,796 |
| 2 | Schedule 2 | FAIRDEAL HEALTH CARE PRIVATE LIMITEDLikely | 4 | ₹2,895.20 |
| 3 | Schedule 3 | EVAAN LIFESCIENCES PRIVATE LIMITEDLikely | 3 | ₹29,400 |
| 4 | Schedule 4 | PRAKASH MEDICOSLikely | 3 | ₹4,026 |
| 5 | Schedule 5 | M/S N.K.CHEMISTLikely | 6 | ₹3,225 |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
20 May 2026, 11:00 amClosed
ECHS CFA RE 06
9287698
GEM/2026/B/7502292
Two Packet Bid
LINAGLIPTIN 5 MG PLUS EMPAGLIFLOZIN 10 MG TAB,RIVAROXABAN 20 MG TAB,RIVASTIGMINE 1 POINT 5MG TAB,RO
Central Delhi, Delhi
Item wise evaluation
BOQ
7 documents required · 7 mandatory
3 yrs
10%
Exempted
Yes
20 May 2026
5 May 2026
20 May 2026
| Item No | Item Title | Qty | Unit | Consignee | Delivery (days) | Spec |
|---|---|---|---|---|---|---|
| 1 | LINAGLIPTIN 5 MG PLUS EMPAGLIFLOZIN 10 MG TAB | 23,800 | No | Central Delhi | 15 | |
| 2 | RIVAROXABAN 20 MG TAB | 1,540 | No | Central Delhi | 15 | |
| 3 | RIVASTIGMINE 1 POINT 5MG TAB | 4,200 | No | Central Delhi | 15 | |
| 4 | ROPINIROLE 0 POINT 25 MG TAB | 3,300 | No | Central Delhi | 15 | |
| 5 | ROPINIROLE 0 POINT 5 MG TAB | 4,300 | No | Central Delhi | 15 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_9287698.pdf
GEM_BID • 0.11 MB
specification_cfa_re_06_2026-05-05-10-22-00_d4c4ac56d137bd6b6779f81282788845.pdf
BOQ • 0.26 MB
boq_item_sample_file_2026-05-05-10-22-00_53fae594c31c6f08047e23a5ea6b8ad2.csv
BOQ • 0.00 MB
GEM_OTHER • 1.82 MB
gtc.pdf
GEM_OTHER • 0.71 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .